研究目的:
Primary Objectives: To evaluate the safety of The Gene Replacement Therapy by rAAV2/8-hCYP4V2 Following a Single Subretinal Administration in The Patients of Bietti's Crystalline Dystrophy (BCD).
Secondary Objectives: To explore the efficacy of The Gene Replacement Therapy by rAAV2/8-hCYP4V2.